Skip to main content

Advertisement

Table 2 Comparison of subject characteristics over time

From: Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study

  FREEDOM baseline Extension baseline End of year 8
Placebo (N = 3906) Denosumab (N = 3902) Crossover denosumab (N = 2207) Long-term denosumab (N = 2343) Crossover denosumab (N = 1462) Long-term denosumab (N = 1542)
Age, years
 Mean (SD) 72.3 (5.2)a 72.3 (5.2)a 74.8 (5.1)b 74.9 (5.0)b 79.0 (4.8) 79.1 (4.7)
 Median (range) 72 (60–91) 72 (60–90) 75 (63–93) 75 (63–93) 79 (68–98) 79 (68–94)
Age group, n (%)
  ≥ 70 years 2878 (74) 2872 (74) 1823 (83) 1974 (84) 1420 (97) 1505 (98)
  ≥ 75 years 1236 (32)a 1235 (32)a 1151 (52)b 1258 (54)b 1160 (79) 1255 (81)
  ≥ 80 years 346 (9) 322 (8) 379 (17) 407 (17) 676 (46) 737 (48)
Prior fracture, n (%)
 Prior vertebral 915 (23)a 929 (24)a 551 (25)b,c 573 (24)b,c NA NA
 Prior nonvertebrald 1177 (30) 1163 (30) 754 (34)c 780 (33)c NA NA
BMD T-score, mean (SD)
 Lumbar spine –2.8 (0.7)a –2.8 (0.7)a –2.8 (0.8)b –2.1 (0.8)b –1.9 (0.9) –1.6 (0.9)
 Total hip –1.9 (0.8)a –1.9 (0.8)a –1.9 (0.8)b –1.5 (0.8)b –1.5 (0.8) –1.3 (0.8)
  1. BMD bone mineral density, NA not applicable (because the prior fractures cannot be defined at the end of the treatment), SD standard deviation
  2. aPublished in Cummings et al, 2009 [1]
  3. bPublished in Papapoulos et al, 2012 [2]
  4. cIncludes incident fractures during FREEDOM
  5. dAt age ≥ 55 years